Managing Elevated LDL-C: New Guidelines and New Agents
Elevated low-density lipoprotein cholesterol (LDL-C) levels are a major contributor to arteriosclerotic cardiovascular disease (ASCVD). In 2018, the AHA and ACC jointly published an updated guideline on blood cholesterol management, providing new guidance on primary and secondary ASCVD prevention including LDL-C threshold levels for treatment and outlining the role of more recently approved agents. In addition, the European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) published guidelines in 2019 that recommended lower LDL-C goal levels, a new definition of high-risk patients that expanded the number of patients in this group, and recommends more aggressive use of non-statin agents compared to the 2018 ACC/AHA guidelines.
Unfortunately, mean LDL-C levels in the US continue to rise. To achieve the AHA’s 2030 impact goal, the new guidelines and new agents will need to be incorporated into clinical practice. This educational activity, “Managing Elevated LDL-C: New Guidelines and New Agents” will provide cardiologists with information about the new guidelines, expert opinion on the role of agents recently approved by the FDA after the guideline publication, and a review of results from trials of agents in late stage development.
This activity is intended for cardiologists and other health care professionals who manage patients with dyslipidemia.
This program is designed to address ACGME and NAM competencies, including delivering patient-centered care and practicing evidence-based medicine.
At the conclusion of this education, participants should be able to:
- Provide individualized primary prevention plans for patients with elevated LDL-C levels using the 2018 cholesterol guidelines
- Develop individualized secondary prevention strategies for patients with elevated LDL-C levels based on recommendations in the 2018 cholesterol guidelines
- Employ adjunctive non-statin agents to intensify LDL-C management when statins alone do not achieve 2018 blood cholesterol guideline goals
- Evaluate the most current efficacy and safety data for non-statin agents approved for managing elevated LDL-C
Seth S. Martin, MD, MHS, FAHA, FACC, FASPC
Associate Professor of Medicine - Cardiology
Johns Hopkins University School of Medicine
Director, Advanced Lipid Disorders Program
Ciccarone Center for the Prevention of Cardiovascular Disease
Seth S. Martin, MD, MHS, FAHA, FACC, FASPC is a preventive cardiologist and clinical lipidologist at Johns Hopkins Hospital in Baltimore, MD. He is a core faculty member in the Ciccarone Center for the Prevention of Cardiovascular Disease, where he directs the lipid clinic and leads mobile health innovations. Dr. Martin also serves as an Associate Faculty member in the Welch Center for Prevention, Epidemiology, and Clinical Research and as Affiliate Faculty in the Malone Center for Engineering in Healthcare. A dedicated clinician and clinical educator, Dr. Martin is a member of the Hopkins Bedside Medicine Faculty. He serves as a Firm Faculty Clinical Coach and Educator with the Janeway Firm of the Osler Medical Residency.
As a prolific researcher and innovator, Dr. Martin led the development of a more precise system for estimating LDL cholesterol. He works with many students, residents, and fellows, with whom he has published more than 200 articles in leading cardiology and medicine journals. He serves as Associate Editor for the American College of Cardiology’s Dyslipidemia Clinical Community and as an Associate Editor for the Journal of Clinical Lipidology. He is an NIH mobile health scholar, and leads a mobile health interest group focused on examining cutting-edge techniques and facilitating interdisciplinary synergy. He is a founder of Corrie Health, a patient-centered digital health platform for cardiovascular prevention. In celebration of the 125th Johns Hopkins Medicine anniversary, Dr. Martin was selected as one of 125 individuals who personify Johns Hopkins Medicine’s mission to improve the health of the community and the world by setting the standard of excellence in medical education, research, and clinical care.
Erin D. Michos, MD, MHS, FAHA, FACC, FASE, FASPC
Associate Professor of Medicine and Epidemiology
Director of Women’s Cardiovascular Health
Associate Director of Preventive Cardiology
Ciccarone Center for the Prevention of Cardiovascular Disease
Division of Cardiology, Johns Hopkins School of Medicine
Erin D. Michos, MD, MHS, FAHA, FACC, FASE, FASPC is an Associate Professor of Medicine in the Division of Cardiology at the Johns Hopkins University School of Medicine, with joint appointment in the Department of Epidemiology at the Johns Hopkins Bloomberg School of Public Health. She is the Director of Women’s Cardiovascular Heath and the Associate Director of Preventive Cardiology with the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease.
Dr. Michos is an internationally known expert in Preventive Cardiology and Women’s Health and has authored over 350 publications. Her research has focused on (1) cardiovascular disease among women; (2) coronary artery calcium, inflammatory markers, and other novel biomarkers of cardiovascular risk prediction; (3) lipids; and (4) vitamin D and other supplements. She is an Associate Editor for the journals of Circulation and the American Journal of Preventive Cardiology.
Dr. Michos is a co-investigator in several National Institute of Health (NIH) studies including the Multi-Ethnic Study of Atherosclerosis (MESA) and the Atherosclerosis Risk in Communities (ARIC) cohorts. Dr. Michos is a faculty mentor for three T32 post-doctoral training grants at Johns Hopkins and the Training Director for three American Heart Association Strategic Focused Research Networks at Johns Hopkins University. As a recognition of her exemplary mentorship, in 2019, she was honored the David Levine Mentoring Award by the Department of Medicine at Johns Hopkins School of Medicine.
Dr. Michos completed medical school at Northwestern University and then completed both Internal Medicine residency and Cardiology fellowship at the Johns Hopkins Hospital. She also completed her Masters of Health Science degree in Cardiovascular Epidemiology at the Johns Hopkins Bloomberg School of Public Health.
DISCLOSURES OF CONFLICTS OF INTEREST
This educational activity has been produced in adherence with the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Nursing Continuing Professional Development (NCPD) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed all activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
Steering Committee Disclosures
The steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Seth S. Martin, MD, MHS, FAHA, FACC, FASPC: Consultant: 89bio, Amgen, AstraZeneca, Esperion
Erin D. Michos, MD, MHS, FAHA, FACC, FASE, FASPC: Nothing to disclose
Robert T. Eberhardt, MD (BUSM Course Director): Nothing to disclose
Non-faculty Content Contributors
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Terry Ann Glauser, MD, MPH; Elizabeth Drury; Natalie Sanfratello, MPH: Nothing to disclose
THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED. IN NO EVENT SHOULD INFORMATION IN THE MATERIALS REGARDING LAWS, REGULATIONS, OR LEGAL LIABILITY BE CONSIDERED LEGAL ADVICE OR USED AS A SUBSTITUTE FOR CONSULTING WITH AN ATTORNEY.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Boston University School of Medicine and Rockpointe. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
PHYSICIAN DESIGNATION STATEMENT
Boston University School of Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For information about the accreditation of this program, please email: [email protected].
ABIM MOC DESIGNATION STATEMENT
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To receive CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through BUSM’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.
MOC APPROVAL STATEMENT
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory, "Managing Elevated LDL-C: New Guidelines and New Agents " has met the requirements as a MOC Part II CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:
MOC Part II CME Activity
MIPS CREDIT DESIGNATION STATEMENT
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).
In order to fulfill requirements for MIPS improvement activity, participants will need to fill out 2 brief follow-up surveys at 30- and 90-days post-activity.
- 1.00 MOC
- 1.00 MOC II
- 1.00 AMA PRA Category 1 Credit™
This course is offered through Rockpointe.
To take this course you will be redirected to Rockpointe's website. You must login or create an account with Rockpointe in order to complete this activity.
Mocingbird works to provide curated, high quality content to our users. Have a suggestion? Want to partner with us? Get in touch!